BioStock: New promising data from Scandion Oncology’s cancer study

05 August 2020 - 11:12

At the end of last week, Scandion Oncology reported phase II data from the first cohort of chemotherapy-resistant colorectal cancer patients treated with the company’s drug candidate SCO-101 in combination with the standard chemotherapy FOLFIRI. The results are encouraging for the further development of the candidate.

Read the full article about Scandion Oncology at

This is a press release from BioStock - Connecting Innovation & Capital

Provided by: Cision
Spotlight (Sweden)
Scandion Oncology A/S
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date